Update for astrocytomas: medical and surgical management considerations

Abstract

Astrocytomas include a wide range of tumors with unique mutations and varying grades of malignancy. These tumors all originate from the astrocyte, a star-shaped glial cell that plays a major role in supporting functions of the central nervous system (CNS), including blood-brain barrier (BBB) development and maintenance, water and ion regulation, influencing neuronal synaptogenesis, and stimulating the immunological response. In terms of epidemiology, glioblastoma (GB), the most common and malignant astrocytoma, generally occur with higher rates in Australia, Western Europe, and Canada, with the lowest rates in Southeast Asia. Additionally, significantly higher rates of GB are observed in males and non-Hispanic whites. It has been suggested that higher levels of testosterone observed in biological males may account for the increased rates of GB. Hereditary syndromes such as Cowden, Lynch, Turcot, Li-Fraumeni, and neurofibromatosis type 1 have been linked to increased rates of astrocytoma development. While there are a number of specific gene mutations that may influence malignancy or be targeted in astrocytoma treatment, O⁶-methylguanine-DNA methyltransferase (MGMT) gene function is an important predictor of astrocytoma response to chemotherapeutic agent temozolomide (TMZ). TMZ for primary and bevacizumab in the setting of recurrent tumor formation are two of the main chemotherapeutic agents currently approved in the treatment of astrocytomas. While stereotactic radiosurgery (SRS) has debatable implications for increased survival in comparison to whole-brain radiotherapy (WBRT), SRS demonstrates increased precision with reduced radiation toxicity. When considering surgical resection of astrocytoma, the extent of resection (EoR) is taken into consideration. Subtotal resection (STR) spares the margins of the T1 enhanced magnetic resonance imaging (MRI) region, gross total resection (GTR) includes the margins, and supramaximal resection (SMR) extends beyond the margin of the T1 and into the T2 region. Surgical resection, radiation, and chemotherapy are integral components of astrocytoma treatment.

Keywords

Astrocytoma / surgical resection / chemotherapy / radiation / glioblastoma / diagnostic imaging

References

[1] Freeman MR. Specification and morphogenesis of astrocytes. Science. 2010;330:774–8.

[2] Wang W. Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study. Biosci Rep. 2019;39:BSR20181968.

[3] Miller KDOstrom QTKruchko CPatil NTihan TCioffi Get al. Brain and other central nervous system tumor statistics, 2021. CA Cancer J Clin. 2021;71:381–406.

[4] Giovannoni FQuintana FJ. The role of astrocytes in CNS inflammation. Trends Immunol. 2020;41:805–19.

[5] Molofsky AVDeneen B. Astrocyte development: a guide for the perplexed. Glia. 2015;63:1320–9.

[6] Batiuk MYMartirosyan AWahis Jde Vin FMarneffe CKusserow Cet al. Identification of region-specific astrocyte subtypes at single cell resolution. Nat Commun. 2020;11:1220.

[7] Herrero-Navarro ÁPuche-Aroca LMoreno-Juan VSempere-Ferràndez AEspinosa ASusín Ret al. Astrocytes and neurons share region-specific transcriptional signatures that confer regional identity to neuronal reprogramming. Sci Adv. 2021;7:eabe8978.

[8] Sathornsumetee SRich JNReardon DA. Diagnosis and treatment of high-grade astrocytoma. Neurol Clin. 2007;25:1111–39.

[9] Hanif FMuzaffar KPerveen KMalhi SMSimjee ShU. Glioblastoma multiforme: a review of its epidemiology and pathogenesis through clinical presentation and treatment. Asian Pac J Cancer Prev. 2017;18:3–9.

[10] Omuro ADeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. JAMA. 2013;310:1842–50.

[11] Chaulagain DSmolanka VSmolanka AMunakomi SHavryliv T. The role of extent of resection on the prognosis of low-grade astrocytoma: a systematic review and meta-analysis. Egypt J Neurosurg. 2022;37:19.

[12] Johnson DRGalanis E. Medical management of high-grade astrocytoma: current and emerging therapies. Semin Oncol. 2014;41:511–22.

[13] Ohgaki HKleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109:93–108.

[14] Leece RXu JOstrom QTChen YKruchko CBarnholtz-Sloan JS. Global incidence of malignant brain and other central nervous system tumors by histology, 2003–2007. Neuro Oncol. 2017;19:1553–64.

[15] Ostrom QTCote DJAscha MKruchko CBarnholtz-Sloan JS. Adult glioma incidence and survival by race or ethnicity in the United States from 2000 to 2014. JAMA Oncol. 2018;4:1254–62.

[16] Costa ARLança de Oliveira MCruz IGonçalves ICascalheira JFSantos CRA. The sex bias of cancer. Trends Endocrinol Metab. 2020;31:785–99.

[17] Bello-Alvarez CCamacho-Arroyo I. Impact of sex in the prevalence and progression of glioblastomas: the role of gonadal steroid hormones. Biol Sex Differ. 2021;12:28.

[18] Carteri RBKopczynski ARodolphi MSStrogulski NRSartor MFeldmann Met al. Testosterone administration after traumatic brain injury reduces mitochondrial dysfunction and neurodegeneration. J Neurotrauma. 2019;36:2246–59.

[19] Rodríguez-Lozano DCVelázquez-Vázquez DEDel Moral-Morales ÁCamacho-Árroyo I. Dihydrotestosterone induces proliferation, migration, and invasion of human glioblastoma cell lines. Onco Targets Ther. 2020;13:8813–23.

[20] Carrano AJuarez JJIncontri DIbarra AGuerrero Cazares H. Sex-specific differences in glioblastoma. Cells. 2021;10:1783.

[21] Davis ME. Epidemiology and overview of gliomas. Semin Oncol Nurs. 2018;34:420–9.

[22] Tabash MA. Characteristics, survival and incidence rates and trends of pilocytic astrocytoma in children in the United States; SEER-based analysis. J Neurol Sci. 2019;400:148–52.

[23] Tykocki TEltayeb M. Ten-year survival in glioblastoma. A systematic review. J Clin Neurosci. 2018;54:7–13.

[24] Hauser ADutta SWShowalter TNSheehan JPGrover STrifiletti DM. Impact of academic facility type and volume on post-surgical outcomes following diagnosis of glioblastoma. J Clin Neurosci. 2018;47:103–10.

[25] Karlsson PHolmberg ELundell MMattsson AHolm LEWallgren A. Intracranial tumors after exposure to ionizing radiation during infancy: a pooled analysis of two Swedish cohorts of 28,008 infants with skin hemangioma. Radiat Res. 1998;150:357–64.

[26] Bondy MLScheurer MEMalmer BBarnholtz-Sloan JSDavis FGIl’yasova Det al.Brain Tumor Epidemiology Consortium. Brain tumor epidemiology: consensus from the Brain Tumor Epidemiology Consortium. Cancer. 2008;113:1953–68.

[27] Chen YHGutmann DH. The molecular and cell biology of pediatric low-grade gliomas. Oncogene. 2014;33:2019–26.

[28] Alcantara Llaguno SChen JKwon CHJackson ELLi YBurns DKet al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell. 2009;15:45–56. Erratum in: Cancer Cell. 2009;15:240.

[29] Carlos-Escalante JÁGómez-Flores-Ramos LBian XPerdomo-Pantoja Áde Ándrade KCMejía-Pérez SIet al. Landscape of germline genetic variants in AGT, MGMT, and TP53 in Mexican adult patients with astrocytoma. Cell Mol Neurobiol. 2021;41:1285–97.

[30] Alentorn ALabussière MSanson MDelattre JYHoang-Xuan KIdbaih Á. Genetics and brain gliomas. Presse Med. 2013;42:806–13. French.

[31] Lynch TMGutmann DH. Neurofibromatosis 1. Neurol Clin. 2002;20:841–65.

[32] Listernick RLouis DNPacker RJGutmann DH. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 Optic Pathway Glioma Task Force. Ann Neurol. 1997;41:143–9.

[33] Stern JJakobiec FAHousepian EM. The architecture of optic nerve gliomas with and without neurofibromatosis. Arch Ophthalmol. 1980;98:505–11.

[34] Kirkpatrick P. Neurosurgical management of aneurysmal subarachnoid haemorrhage. J Neurol Neurosurg Psychiatry. 2000;68:538E.

[35] Perdomo-Pantoja AMejía-Pérez SIReynoso-Noverón NGómez-Flores-Ramos LSoto-Reyes ESánchez-Correa TEet al. Ángiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma. PLoS One. 2018;13:e0206590.

[36] Wang TSun YXiong ZWu JDing XGuo Xet al. Association of ST6GAL1 and CYP19A1 polymorphisms in the 3’-UTR with astrocytoma risk and prognosis in a Chinese Han population. BMC Cancer. 2021;21:391.

[37] The genetics of cancer [Internet]. Credit the National Cancer Institute as the source; [cited 2022 Aug 10]. Available from: https://www.cancer.gov/about-cancer/causes-prevention/genetics

[38] Welcsh PLKing MC. BRCA1 and BRCA2 and the genetics of breast and ovarian cancer. Hum Mol Genet. 2001;10:705–13.

[39] Guha TMalkin D. Inherited TP53 mutations and the Li-Fraumeni syndrome. Cold Spring Harb Perspect Med. 2017;7:a026187.

[40] IDH1 isocitrate dehydrogenase (NADP(+)) 1 [ Homo sapiens (human) ] [Internet]. Courtesy of the National Library of Medicine; [cited 2022 Aug 11]. Available from: https://www.ncbi.nlm.nih.gov/gene/3417

[41] IDH2 isocitrate dehydrogenase (NADP(+)) 2 [ Homo sapiens (human) ] [Internet]. Courtesy of the National Library of Medicine; [cited 2022 Aug 11]. Available from: https://www.ncbi.nlm.nih.gov/gene/3418

[42] Mondesir JWillekens CTouat Mde Botton S. IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives. J Blood Med. 2016;7:171–80.

[43] Reitman ZJYan H. Isocitrate dehydrogenase 1 and 2 mutations in cancer: alterations at a crossroads of cellular metabolism. J Natl Cancer Inst. 2010;102:932–41.

[44] Dang LWhite DWGross SBennett BDBittinger MADriggers EMet al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature. 2009;462:739–44.

[45] van den Bent MJDubbink HJMarie YBrandes AATaphoorn MJWesseling Pet al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin Cancer Res. 2010;16:1597–604.

[46] Alifieris CTrafalis DT. Glioblastoma multiforme: pathogenesis and treatment. Pharmacol Ther. 2015;152:63–82.

[47] Hartmann CHentschel BWick WCapper DFelsberg JSimon Met al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120:707–18.

[48] MGMT O-6-methylguanine-DNA methyltransferase [ Homo sapiens (human) ] [Internet]. Courtesy of the National Library of Medicine; [cited 2022 Aug 11]. Available from: https://www.ncbi.nlm.nih.gov/gene/4255

[49] Tomar MSKumar ASrivastava CShrivastava A. Elucidating the mechanisms of temozolomide resistance in gliomas and the strategies to overcome the resistance. Biochim Biophys Acta Rev Cancer. 2021;1876:188616.

[50] Hegi MEDiserens ACGorlia THamou MFde Tribolet NWeller Met al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med. 2005;352:997–1003.

[51] Minniti GScaringi CArcella ALanzetta GDi Stefano DScarpino Set al. IDH1 mutation and MGMT methylation status predict survival in patients with anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. J Neurooncol. 2014;118:377–83.

[52] Hosoya TTakahashi MHonda-Kitahara MMiyakita YOhno MYanagisawa Set al. MGMT gene promoter methylation by pyrosequencing method correlates volumetric response and neurological status in IDH wild-type glioblastomas. J Neurooncol. 2022;157:561–71.

[53] Servier Medical Art [Internet]. [cited 2022 Jan 28]. Available from: https://smart.servier.com

[54] Muldoon LLAlvarez JIBegley DJBoado RJDel Zoppo GJDoolittle NDet al. Immunologic privilege in the central nervous system and the blood-brain barrier. J Cereb Blood Flow Metab. 2013;33:13–21.

[55] Peruzzi PPrabhu V. Astrocytoma tumors [Internet]. Rolling Meadows: American Association of Neurological Surgeons; 2023 [cited 2022 Aug 10]. Available from: https://www.aans.org/Patients/Neurosurgical-Conditions-and-Treatments/Astrocytoma-Tumors

[56] Brown NFCarter TJOttaviani DMulholland P. Harnessing the immune system in glioblastoma. Br J Cancer. 2018;119:1171–81.

[57] Didenko VVNgo HNMinchew CBaskin DS. Apoptosis of T lymphocytes invading glioblastomas multiforme: a possible tumor defense mechanism. J Neurosurg. 2002;96:580–4.

[58] Bodmer SStrommer KFrei KSiepl Cde Tribolet NHeid Iet al. Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2. J Immunol. 1989;143:3222–9.

[59] Pearson JRDCuzzubbo SMcArthur SDurrant LGAdhikaree JTinsley CJet al. Immune escape in glioblastoma multiforme and the adaptation of immunotherapies for treatment. Front Immunol. 2020;11:582106.

[60] Zhang HLiao JZhang XZhao ELiang XLuo Set al. Sex difference of mutation clonality in diffuse glioma evolution. Neuro Oncol. 2019;21:201–13.

[61] Claus EBCannataro VLGaffney SGTownsend JP. Environmental and sex-specific molecular signatures of glioma causation. Neuro Oncol. 2022;24:29–36. Erratum in: Neuro Oncol. 2022;24:2012.

[62] Louis DNPerry AReifenberger Gvon Deimling AFigarella-Branger DCavenee WKet al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. 2016;131:803–20.

[63] Mamelak ANPrados MDObana WGCogen PHEdwards MS. Treatment options and prognosis for multicentric juvenile pilocytic astrocytoma. J Neurosurg. 1994;81:24–30.

[64] Johnson DRBrown PDGalanis EHammack JE. Pilocytic astrocytoma survival in adults: analysis of the Surveillance, Epidemiology, and End Results program of the National Cancer Institute. J Neurooncol. 2012;108:187–93.

[65] Dirven CMMooij JJMolenaar WM. Cerebellar pilocytic astrocytoma: a treatment protocol based upon analysis of 73 cases and a review of the literature. Childs Nerv Syst. 1997;13:17–23.

[66] Komotar RJBurger PCCarson BSBrem HOlivi AGoldthwaite PTet al. Pilocytic and pilomyxoid hypothalamic/chiasmatic astrocytomas. Neurosurgery. 2004;54:72–80.

[67] Fernandez CFigarella-Branger DGirard NBouvier-Labit CGouvernet JPaz Paredes Aet al. Pilocytic astrocytomas in children: prognostic factors—a retrospective study of 80 cases. Neurosurgery. 2003;53:544–55.

[68] Bornhorst MFrappaz DPacker RJ. Chapter 20 - Pilocytic astrocytomas. In: Berger MS, Weller M, editors. Handb Clin Neurol. Elsevier; 2016. pp. 329–44.

[69] Mair MJWöhrer AFurtner JSimonovska AKiesel BOberndorfer Set al. Clinical characteristics and prognostic factors of adult patients with pilocytic astrocytoma. J Neurooncol. 2020;148:187–98.

[70] Tahiri Elousrouti LLamchahab MBougtoub NElfatemi HChbani LHarmouch Tet al. Subependymal giant cell astrocytoma (SEGA): a case report and review of the literature. J Med Case Rep. 2016;10:35.

[71] Campen CJPorter BE. Subependymal giant cell astrocytoma (SEGA) treatment update. Curr Treat Options Neurol. 2011;13:380–5.

[72] Ryall STabori UHawkins C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol Commun. 2020;8:30.

[73] Liu SLiu XZhuang W. Prognostic factors associated with survival in patients with diffuse astrocytoma. Front Surg. 2021;8:712350.

[74] Chiang JHarreld JHTinkle CLMoreira DCLi XAcharya Set al. A single-center study of the clinicopathologic correlates of gliomas with a MYB or MYBL1 alteration. Acta Neuropathol. 2019;138:1091–2.

[75] Louis DNPerry AWesseling PBrat DJCree IAFigarella-Branger Det al. The 2021 WHO classification of tumors of the central nervous system: a summary. Neuro Oncol. 2021;23:1231–51.

[76] Wessels PHWeber WERaven GRamaekers FCHopman AHTwijnstra A. Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol. 2003;2:395–403.

[77] Lind-Landström THabberstad AHSundstrøm STorp SH. Prognostic value of histological features in diffuse astrocytomas WHO grade II. Int J Clin Exp Pathol. 2012;5:152–8.

[78] Zhang FLiu YZhang ZLi JWan YZhang Let al. 5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas. Sci Rep. 2016;6:20882.

[79] Chen JRYao YXu HZQin ZY. Isocitrate dehydrogenase (IDH)1/2 mutations as prognostic markers in patients with glioblastomas. Medicine (Baltimore). 2016;95:e2583.

[80] Cancer Genome Atlas Research NetworkBrat DJVerhaak RGAldape KDYung WKSalama SRCooper LAet al. Comprehensive, integrative genomic analysis of diffuse lower-grade gliomas. N Engl J Med. 2015;372:2481–98.

[81] Thon NEigenbrod SKreth SLutz JTonn JCKretzschmar Het al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-free survival and prolonged postrecurrence survival. Cancer. 2012;118:452–60.

[82] Ahmadi RStockhammer FBecker NHohlen KMisch MChristians Aet al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas. J Neurooncol. 2012;109:15–22.

[83] Dong XNoorbakhsh AHirshman BRZhou TTang JAChang DCet al. Survival trends of grade I, II, and III astrocytoma patients and associated clinical practice patterns between 1999 and 2010: a SEER-based analysis. Neurooncol Pract. 2016;3:29–38.

[84] Shaikh NBrahmbhatt NKruser TJKam KLAppin CLWadhwani Net al. Pleomorphic xanthoastrocytoma: a brief review. CNS Oncol. 2019;8:CNS39.

[85] Lim SKim JHKim SAPark ESRa YSKim CJ. Prognostic factors and therapeutic outcomes in 22 patients with pleomorphic xanthoastrocytoma. J Korean Neurosurg Soc. 2013;53:281–7.

[86] Brandes AANicolardi LTosoni AGardiman MIuzzolino PGhimenton Cet al. Survival following adjuvant PCV or temozolomide for anaplastic astrocytoma. Neuro Oncol. 2006;8:253–60.

[87] Lakomy RKazda TSelingerova IPoprach APospisil PBelanova Ret al. Real-world evidence in glioblastoma: Stupp’s regimen after a decade. Front Oncol. 2020;10:840.

[88] Christians AAdel-Horowski ABanan RLehmann UBartels SBehling Fet al. The prognostic role of IDH mutations in homogeneously treated patients with anaplastic astrocytomas and glioblastomas. Acta Neuropathol Commun. 2019;7:156.

[89] Yang WXu TGarzon-Muvdi TJiang CHuang JChaichana KL. Survival of ventricular and periventricular high-grade gliomas: a Surveillance, Epidemiology, and End Results program-based study. World Neurosurg. 2018;111:e323–34.

[90] Fyllingen EHBø LEReinertsen IJakola ASSagberg LMBerntsen EMet al. Survival of glioblastoma in relation to tumor location: a statistical tumor atlas of a population-based cohort. Acta Neurochir (Wien). 2021;163:1895–905.

[91] Osborn AGLouis DNPoussaint TYLinscott LLSalzman KL. The 2021 World Health Organization classification of tumors of the central nervous system: what neuroradiologists need to know. AJNR Am J Neuroradiol. 2022;43:928–37.

[92] McNamara CMankad KThust SDixon LLimback-Stanic CD’Arco Fet al. 2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist. Neuroradiology. 2022;64:1919–50.

[93] Mechtler L. Neuroimaging in neuro-oncology. Neurol Clin. 2009;27:171–201.

[94] Pierallini ABonamini MBozzao APantano PStefano DDFerone Eet al. Supratentorial diffuse astrocytic tumours: proposal of an MRI classification. Eur Radiol. 1997;7:395–9.

[95] Tervonen OForbes GScheithauer BWDietz MJ. Diffuse “fibrillary” astrocytomas: correlation of MRI features with histopathologic parameters and tumor grade. Neuroradiology. 1992;34:173–8.

[96] Watanabe MTanaka RTakeda N. Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology. 1992;34:463–9.

[97] Shukla GAlexander GSBakas SNikam RTalekar KPalmer JDet al. Advanced magnetic resonance imaging in glioblastoma: a review. Chin Clin Oncol. 2017;6:40.

[98] Kono KInoue YNakayama KShakudo MMorino MOhata Ket al. The role of diffusion-weighted imaging in patients with brain tumors. AJNR Am J Neuroradiol. 2001;22:1081–8.

[99] de Fatima Vasco Aragao MLaw MBatista de Almeida DFatterpekar GDelman BBader ASet al. Comparison of perfusion, diffusion, and MR spectroscopy between low-grade enhancing pilocytic astrocytomas and high-grade astrocytomas. AJNR Am J Neuroradiol. 2014;35:1495–502.

[100] Abdullah KGLubelski DNucifora PGBrem S. Use of diffusion tensor imaging in glioma resection. Neurosurg Focus. 2013;34:E1.

[101] Lee SK. Diffusion tensor and perfusion imaging of brain tumors in high-field MR imaging. Neuroimaging Clin N Am. 2012;22:123–34.

[102] Kim RChoi SHYun TJLee STPark CKKim TMet al. Prognosis prediction of non-enhancing T2 high signal intensity lesions in glioblastoma patients after standard treatment: application of dynamic contrast-enhanced MR imaging. Eur Radiol. 2017;27:1176–85.

[103] Chakravorty ASteel TChaganti J. Accuracy of percentage of signal intensity recovery and relative cerebral blood volume derived from dynamic susceptibility-weighted, contrast-enhanced MRI in the preoperative diagnosis of cerebral tumours. Neuroradiol J. 2015;28:574–83.

[104] Bulakbaşı NPaksoy Y. Ádvanced imaging in adult diffusely infiltrating low-grade gliomas. Insights Imaging. 2019;10:122. Erratum in: Insights Imaging. 2020;11:57.

[105] Porto LKieslich MFranz KLehrbecher TVlaho SPilatus Uet al. Spectroscopy of untreated pilocytic astrocytomas: do children and adults share some metabolic features in addition to their morphologic similarities? Childs Nerv Syst. 2010;26:801–6.

[106] Krouwer HGDavis RLSilver PPrados M. Gemistocytic astrocytomas: a reappraisal. J Neurosurg. 1991;74:399–406.

[107] Simkin PMYang NTsui AKalnins RMFitt GGaillard F. Magnetic resonance imaging features of gemistocytic astrocytoma. J Med Imaging Radiat Oncol. 2016;60:733–40.

[108] Joyner DAGarrett JBatchala PPRama BRavicz JRPatrie JTet al. MRI features predict tumor grade in isocitrate dehydrogenase (IDH)-mutant astrocytoma and oligodendroglioma. Neuroradiology. 2023;65:121–9.

[109] Kim YZKim CYLim DH. The overview of practical guidelines for gliomas by KSNO, NCCN, and EANO. Brain Tumor Res Treat. 2022;10:83–93.

[110] Salazar OMRubin PFeldstein MLPizzutiello R. High dose radiation therapy in the treatment of malignant gliomas: final report. Int J Radiat Oncol Biol Phys. 1979;5:1733–40.

[111] Salazar OMVanHoutte PJBennett JMRubin PWheeler KT. High-dose radiation therapy with low-dose (pulsed) BCNU in malignant gliomas: an eastern cooperative oncology group (ECOG) report. Int J Radiat Oncol Biol Phys. 1982;8:915–9.

[112] Walker MDStrike TASheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas. Int J Radiat Oncol Biol Phys. 1979;5:1725–31.

[113] Chen JCGirvigian MR. Stereotactic radiosurgery: instrumentation and theoretical aspects—part 1. Perm J. 2005;9:23–6.

[114] Yanagihara TKSaadatmand HJWang TJ. Reevaluating stereotactic radiosurgery for glioblastoma: new potential for targeted dose-escalation. J Neurooncol. 2016;130:397–411.

[115] Minniti GScaringi CLanzetta GTerrenato IEsposito VArcella Aet al. Standard (60 Gy) or short-course (40 Gy) irradiation plus concomitant and adjuvant temozolomide for elderly patients with glioblastoma: a propensity-matched analysis. Int J Radiat Oncol Biol Phys. 2015;91:109–15.

[116] Niyazi MBrada MChalmers AJCombs SEErridge SCFiorentino Aet al. ESTRO-ACROP guideline “target delineation of glioblastomas”. Radiother Oncol. 2016;118:35–42.

[117] Kong DSLee JIPark KKim JHLim DHNam DH. Efficacy of stereotactic radiosurgery as a salvage treatment for recurrent malignant gliomas. Cancer. 2008;112:2046–51.

[118] Zeng JSee APPhallen JJackson CMBelcaid ZRuzevick Jet al. Anti-PD-1 blockade and stereotactic radiation produce long-term survival in mice with intracranial gliomas. Int J Radiat Oncol Biol Phys. 2013;86:343–9.

[119] Cabrera ARKirkpatrick JPFiveash JBShih HAKoay EJLutz Set al. Radiation therapy for glioblastoma: executive summary of an American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol. 2016;6:217–25.

[120] Weller Mvan den Bent MTonn JCStupp RPreusser MCohen-Jonathan-Moyal Eet al.European Association for Neuro-Oncology (EANO) Task Force on Gliomas. European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas. Lancet Oncol. 2017;18:e315–29. Erratum in: Lancet Oncol. 2017;18:e642.

[121] Sepúlveda-Sánchez JMMuñoz Langa JArráez MÁFuster JHernández Laín ÁReynés Get al. Correction to: SEOM clinical guideline of diagnosis and management of low-grade glioma (2017). Clin Transl Oncol. 2018;20:108–9. Erratum for: Clin Transl Oncol. 2018;20:3–15.

[122] Tatar ZThivat EPlanchat EGimbergues PGadea EAbrial Cet al. Temozolomide and unusual indications: review of literature. Cancer Treat Rev. 2013;39:125–35.

[123] Stupp RMason WPvan den Bent MJWeller MFisher BTaphoorn MJet al.European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups, National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352:987–96.

[124] Stupp RHegi MEMason WPvan den Bent MJTaphoorn MJJanzer RCet al.European Organisation for Research and Treatment of Cancer Brain Tumour and Radiation Oncology Groups, National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009;10:459–66.

[125] Herrlinger UTzaridis TMack FSteinbach JPSchlegel USabel Met al.Neurooncology Working Group of the German Cancer Society. Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a randomised, open-label, phase 3 trial. Lancet. 2019;393:678–88.

[126] Baumert BGHegi MEvan den Bent MJvon Deimling AGorlia THoang-Xuan Ket al. Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup study. Lancet Oncol. 2016;17:1521–32.

[127] Mohile NAMessersmith HGatson NTHottinger AFLassman AMorton Jet al. Therapy for diffuse astrocytic and oligodendroglial tumors in adults: ASCO-SNO guideline. J Clin Oncol. 2022;40:403–26.

[128] Kreisl TNKim LMoore KDuic PRoyce CStroud Iet al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol. 2009;27:740–5.

[129] Gilbert MRDignam JJArmstrong TSWefel JSBlumenthal DTVogelbaum MAet al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370:699–708.

[130] Chinot OLWick WMason WHenriksson RSaran FNishikawa Ret al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014;370:709–22.

[131] Gil-Gil MJMesia CRey MBruna J. Bevacizumab for the treatment of glioblastoma. Clin Med Insights Oncol. 2013;7:CMO.S8503.

[132] Sathornsumetee SDesjardins AVredenburgh JJMcLendon REMarcello JHerndon JEet al. Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol. 2010;12:1300–10.

[133] Reardon DADesjardins AVredenburgh JJGururangan SSampson JHSathornsumetee Set al. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study. Br J Cancer. 2009;101:1986–94.

[134] Verhoeff JJCLavini Cvan Linde MEStalpers LJAMajoie CBLMReijneveld JCet al. Bevacizumab and dose-intense temozolomide in recurrent high-grade glioma. Ann Oncol. 2010;21:1723–7.

[135] Soffietti RTrevisan EBertero LCassoni PMorra IFabrini MGet al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology). J Neurooncol. 2014;116:533–41.

[136] Hasselbalch BLassen UHansen SHolmberg MSørensen MKosteljanetz Met al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma and progression after radiation therapy and temozolomide: a phase II trial. Neuro Oncol. 2010;12:508–16.

[137] Wick WGorlia TBendszus MTaphoorn MSahm FHarting Iet al. Lomustine and bevacizumab in progressive glioblastoma. N Engl J Med. 2017;377:1954–63.

[138] Armstrong TSGilbert MR. Chemotherapy of astrocytomas: an overview. Semin Oncol Nurs. 1998;14:18–25.

[139] Fine HADear KBLoeffler JSBlack PMCanellos GP. Meta-analysis of radiation therapy with and without adjuvant chemotherapy for malignant gliomas in adults. Cancer. 1993;71:2585–97.

[140] Cairncross GMacdonald DLudwin SLee DCascino TBuckner Jet al. Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1994;12:2013–21.

[141] Levin VASilver PHannigan JWara WMGutin PHDavis RLet al. Superiority of post-radiotherapy adjuvant chemotherapy with CCNU, procarbazine, and vincristine (PCV) over BCNU for anaplastic gliomas: NCOG 6G61 final report. Int J Radiat Oncol Biol Phys. 1990;18:321–4.

[142] Grimm SAChamberlain MC. State of the art and perspectives in the treatment of glioblastoma. CNS Oncol. 2012;1:49–70.

[143] Fokas EWacker UGross MWHenzel MEncheva EEngenhart-Cabillic R. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial treatment option after high-dose radiotherapy? Strahlenther Onkol. 2009;185:235–40.

[144] Diaz RJAli SQadir MGDe La Fuente MIIvan MEKomotar RJ. The role of bevacizumab in the treatment of glioblastoma. J Neurooncol. 2017;133:455–67.

[145] Jakobsen JNUrup TGrunnet KToft AJohansen MDPoulsen SHet al. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients. J Neurooncol. 2018;137:439–46.

[146] Minniti GNiyazi MAlongi FNavarria PBelka C. Current status and recent advances in reirradiation of glioblastoma. Radiat Oncol. 2021;16:36.

[147] De Leeuw BIVan Baarsen KMSnijders TJRobe PAJT. Interrelationships between molecular subtype, anatomical location, and extent of resection in diffuse glioma: a systematic review and meta-analysis. Neurooncol Adv. 2019;1:vdz032.

[148] Bonfield CMSteinbok P. Pediatric cerebellar astrocytoma: a review. Childs Nerv Syst. 2015;31:1677–85.

[149] Davis ME. Glioblastoma: overview of disease and treatment. Clin J Oncol Nurs. 2016;20:S2–8.

[150] Dimou JBeland BKelly J. Supramaximal resection: a systematic review of its safety, efficacy and feasibility in glioblastoma. J Clin Neurosci. 2020;72:328–34.

[151] Di Carlo DTDuffau HCagnazzo FBenedetto NMorganti RPerrini P. IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis. Neurosurg Rev. 2020;43:383–95.

[152] Brown TJBota DAvan Den Bent MJBrown PDMaher EAregawi Det al. Management of low-grade glioma: a systematic review and meta-analysis. Neurooncol Pract. 2019;6:249–58.

[153] Nagoshi NTsuji OSuzuki SNori SYagi MOkada Eet al. Clinical outcomes and a therapeutic indication of intramedullary spinal cord astrocytoma. Spinal Cord. 2022;60:216–22.

[154] Ogunlade JWiginton JG 4thElia COdell TRao SC. Primary spinal astrocytomas: a literature review. Cureus. 2019;11:e5247.

[155] Khalafallah AMRakovec MBettegowda CJackson CMGallia GLWeingart JDet al. A crowdsourced consensus on supratotal resection versus gross total resection for anatomically distinct primary glioblastoma. Neurosurgery. 2021;89:712–9.

[156] Jackson CChoi JKhalafallah AMPrice CBettegowda CLim Met al. A systematic review and meta-analysis of supratotal versus gross total resection for glioblastoma. J Neurooncol. 2020;148:419–31.

[157] Barajas RFJrPhillips JJParvataneni RMolinaro AEssock-Burns EBourne Get al. Regional variation in histopathologic features of tumor specimens from treatment-naive glioblastoma correlates with anatomic and physiologic MR Imaging. Neuro Oncol. 2012;14:942–54.

[158] Eidel OBurth SNeumann JOKieslich PJSahm FJungk Cet al. Tumor infiltration in enhancing and non-enhancing parts of glioblastoma: a correlation with histopathology. PLoS One. 2017;12:e0169292.

[159] Kubben PLWesseling PLammens MSchijns OETer Laak-Poort MPvan Overbeeke JJet al. Correlation between contrast enhancement on intraoperative magnetic resonance imaging and histopathology in glioblastoma. Surg Neurol Int. 2012;3:158.

[160] Haddad AFYoung JSMorshed RABerger MS. FLAIRectomy: resecting beyond the contrast margin for glioblastoma. Brain Sci. 2022;12:544.

[161] Li YMSuki DHess KSawaya R. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: can we do better than gross-total resection? J Neurosurg. 2016;124:977–88.

[162] Vivas-Buitrago TDomingo RATripathi SDe Biase GBrown DAkinduro OOet al. Influence of supramarginal resection on survival outcomes after gross-total resection of IDH-wild-type glioblastoma. J Neurosurg. 2021;136:1–8.

[163] Pessina FNavarria PCozzi LAscolese AMSimonelli MSantoro Aet al. Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience. J Neurooncol. 2017;135:129–39.

[164] Tripathi SVivas-Buitrago TDomingo RABiase GDBrown DAkinduro OOet al. IDH-wild-type glioblastoma cell density and infiltration distribution influence on supramarginal resection and its impact on overall survival: a mathematical model. J Neurosurg. 2022;136:1567–75.

[165] Di LShah AHMahavadi AEichberg DGReddy RSanjurjo ADet al. Radical supramaximal resection for newly diagnosed left-sided eloquent glioblastoma: safety and improved survival over gross-total resection. J Neurosurg. 2022;138:62–9.

[166] Glenn CABaker CMConner AKBurks JDBonney PABriggs RGet al. An examination of the role of supramaximal resection of temporal lobe glioblastoma multiforme. World Neurosurg. 2018;114:e747–55.

[167] Lopez-Rivera VDono ALewis CTChandra AAbdelkhaleq RSheth SAet al. Extent of resection and survival outcomes of geriatric patients with glioblastoma: is there benefit from aggressive surgery? Clin Neurol Neurosurg. 2021;202:106474.

[168] Shah AHMahavadi ADi LSanjurjo AEichberg DGBorowy Vet al. Survival benefit of lobectomy for glioblastoma: moving towards radical supramaximal resection. J Neurooncol. 2020;148:501–8.

[169] Lukas RVWainwright DALadomersky ESachdev SSonabend AMStupp R. Newly diagnosed glioblastoma: a review on clinical management. Oncology (Williston Park). 2019;33:91–100.

[170] Ma RTaphoorn MJBPlaha P. Advances in the management of glioblastoma. J Neurol Neurosurg Psychiatry. 2021;92:1103–11.

[171] Matsumae MNishiyama JKuroda K. Intraoperative MR imaging during glioma resection. Magn Reson Med Sci. 2022;21:148–67.

[172] Coburger JScheuerle AKapapa TEngelke JThal DRWirtz CRet al. Sensitivity and specificity of linear array intraoperative ultrasound in glioblastoma surgery: a comparative study with high field intraoperative MRI and conventional sector array ultrasound. Neurosurg Rev. 2015;38:499–509.

[173] Tanaka STashiro TGomi ATakanashi JUjiie H. Sensitivity and specificity in transcranial motor-evoked potential monitoring during neurosurgical operations. Surg Neurol Int. 2011;2:111.

[174] Traylor JIPernik MNSternisha ACMcBrayer SKAbdullah KG. Molecular and metabolic mechanisms underlying selective 5-aminolevulinic acid-induced fluorescence in gliomas. Cancers (Basel). 2021;13:580.

[175] Smith EJGohil KThompson CMNaik AHassaneen W. Fluorescein-guided resection of high grade gliomas: a meta-analysis. World Neurosurg. 2021;155:181–8.e7.

[176] Gandhi STayebi Meybodi ABelykh ECavallo CZhao XSyed MPet al. Survival outcomes among patients with high-grade glioma treated with 5-aminolevulinic acid-guided surgery: a systematic review and meta-analysis. Front Oncol. 2019;9:620.

[177] Zhang NTian HHuang DMeng XGuo WWang Cet al. Sodium fluorescein-guided resection under the YELLOW 560 nm surgical microscope filter in malignant gliomas: our first 38 cases experience. Biomed Res Int. 2017;2017:7865747. Erratum in: Biomed Res Int. 2018;2018:6348625.

[178] Naik ASmith EJBarreau ANyaeme MCramer SWNajafali Det al. Comparison of fluorescein sodium, 5-ALA, and intraoperative MRI for resection of high-grade gliomas: a systematic review and network meta-analysis. J Clin Neurosci. 2022;98:240–7.

[179] Zeppa PDe Marco RMonticelli MMassara ABianconi ADi Perna Get al. Fluorescence-guided surgery in glioblastoma: 5-ALA, SF or both? Differences between fluorescent dyes in 99 consecutive cases. Brain Sci. 2022;12:555.

[180] Clavreul AAubin GDelion MLemée JMTer Minassian AMenei P. What effects does awake craniotomy have on functional and survival outcomes for glioblastoma patients? J Neurooncol. 2021;151:113–21.

[181] Sacko OLauwers-Cances VBrauge DSesay MBrenner ARoux FE. Awake craniotomy vs surgery under general anesthesia for resection of supratentorial lesions. Neurosurgery. 2011;68:1192–9.

[182] Gravesteijn BYKeizer MEVincent AJPESchouten JWStolker RJKlimek M. Awake craniotomy versus craniotomy under general anesthesia for the surgical treatment of insular glioma: choices and outcomes. Neurol Res. 2018;40:87–96.

[183] Suarez-Meade PMarenco-Hillembrand LPrevatt CMurguia-Fuentes RMohamed AAlsaeed Tet al. Awake vs. asleep motor mapping for glioma resection: a systematic review and meta-analysis. Acta Neurochir (Wien). 2020;162:1709–20.

[184] Zhang JJYLee KSVoisin MRHervey-Jumper SLBerger MSZadeh G. Awake craniotomy for resection of supratentorial glioblastoma: a systematic review and meta-analysis. Neurooncol Adv. 2020;2:vdaa111.

[185] Zigiotto LAnnicchiarico LCorsini FVitali LFalchi RDalpiaz Cet al. Effects of supra-total resection in neurocognitive and oncological outcome of high-grade gliomas comparing asleep and awake surgery. J Neurooncol. 2020;148:97–108.

[186] Bu LHZhang JLu JFWu JS. Glioma surgery with awake language mapping versus generalized anesthesia: a systematic review. Neurosurg Rev. 2021;44:1997–2011.

[187] Moiraghi ARoux APeeters SPelletier JBBaroud MTrancart Bet al. Feasibility, safety and impact on overall survival of awake resection for newly diagnosed supratentorial IDH-wildtype glioblastomas in adults. Cancers (Basel). 2021;13:2911.

[188] Lu VMPhan KRovin RA. Comparison of operative outcomes of eloquent glioma resection performed under awake versus general anesthesia: a systematic review and meta-analysis. Clin Neurol Neurosurg. 2018;169:121–7.

[189] Gerritsen JKWZwarthoed RHKilgallon JLNawabi NLJessurun CACVersyck Get al. Effect of awake craniotomy in glioblastoma in eloquent areas (GLIOMAP): a propensity score-matched analysis of an international, multicentre, cohort study. Lancet Oncol. 2022;23:802–17.

[190] Gerritsen JKWDirven CMFDe Vleeschouwer SSchucht PJungk CKrieg SMet al. The PROGRAM study: awake mapping versus asleep mapping versus no mapping for high-grade glioma resections: study protocol for an international multicenter prospective three-arm cohort study. BMJ Open. 2021;11:e047306. Erratum in: BMJ Open. 2022;12:e047306corr1.

[191] Gerritsen JKWKlimek MDirven CMFHoop EOWagemakers MRutten GJMet al. The SAFE-trial: Safe surgery for glioblastoma multiforme: awake craniotomy versus surgery under general anesthesia. Study protocol for a multicenter prospective randomized controlled trial. Contemp Clin Trials. 2020;88:105876.

[192] Wu ALim M. The challenges and future of immunotherapy for gliomas. Cancer J. 2021;27:371–8.

[193] Liang MGao CWang YGong WFu SCui Let al. Enhanced blood-brain barrier penetration and glioma therapy mediated by T7 peptide-modified low-density lipoprotein particles. Drug Deliv. 2018;25:1652–63.

[194] Agarwala SSKirkwood JM. Temozolomide, a novel alkylating agent with activity in the central nervous system, may improve the treatment of advanced metastatic melanoma. Oncologist. 2000;5:144–51.

[195] Mehta AMSonabend AMBruce JN. Convection-enhanced delivery. Neurotherapeutics. 2017;14:358–71.

[196] Gregory JVKadiyala PDoherty RCadena MHabeel SRuoslahti Eet al. Systemic brain tumor delivery of synthetic protein nanoparticles for glioblastoma therapy. Nat Commun. 2020;11:5687.

[197] Shah AHHeiss JD. Neurosurgical clinical trials for glioblastoma: current and future directions. Brain Sci. 2022;12:787.

[198] Vogelbaum MABrewer CBarnett GHMohammadi AMPeereboom DMAhluwalia MSet al. First-in-human evaluation of the Cleveland Multiport Catheter for convection-enhanced delivery of topotecan in recurrent high-grade glioma: results of pilot trial 1. J Neurosurg. 2019;130:476–85.

[199] Piperi CPapavassiliou KAPapavassiliou AG. Pivotal role of STAT3 in shaping glioblastoma immune microenvironment. Cells. 2019;8:1398.

[200] McNutt M. Cancer immunotherapy. Science. 2013;342:1417.

[201] Mellman ICoukos GDranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480–9.

[202] Topalian SLDrake CGPardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27:450–61.

[203] Rong LLi NZhang Z. Emerging therapies for glioblastoma: current state and future directions. J Exp Clin Cancer Res. 2022;41:142.

[204] Gholamin SMitra SSFeroze AHLiu JKahn SAZhang Met al. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Sci Transl Med. 2017;9:eaaf2968.

[205] Vijayan DYoung ATeng MWLSmyth MJ. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer. 2017;17:765. Erratum for: Nat Rev Cancer. 2017;17:709–24.

[206] Caccese MPadovan MD’Avella DChioffi FGardiman MPBerti Fet al. Anaplastic astrocytoma: state of the art and future directions. Crit Rev Oncol Hematol. 2020;153:103062.

[207] Kaley TTouat MSubbiah VHollebecque ARodon JLockhart ACet al. BRAF inhibition in BRAF^V600-mutant gliomas: results from the VE-BASKET study. J Clin Oncol. 2018;36:3477–84.

[208] Bahleda RItaliano AHierro CMita ACervantes AChan Net al. Multicenter phase I study of erdafitinib (JNJ-42756493), oral pan-fibroblast growth factor receptor inhibitor, in patients with advanced or refractory solid tumors. Clin Cancer Res. 2019;25:4888–97.

[209] Schindler GCapper DMeyer JJanzarik WOmran HHerold-Mende Cet al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 2011;121:397–405.